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ARTICLE
Clinical and epidemiological profiles of 
non-traumatic myelopathies
Perfil clínico e epidemiológico das mielopatias não-traumáticas 
Wladimir Bocca Vieira de Rezende Pinto, Paulo Victor Sgobbi de Souza, Marcus Vinícius Cristino de 
Albuquerque, Lívia Almeida Dutra, José Luiz Pedroso, Orlando Graziani Povoas Barsottini
Non-traumatic spinal cord diseases constitute one 
of the most common groups of neurological diseases in 
medical practice1. It is a broad and heterogeneous group 
of etiologies, summarily divided into compressive and 
non-compressive, among which include infectious, de-
myelinating, neoplastic, metabolic and vascular diseas-
es and congenital malformations. Medical comorbidities 
and epidemiological data are important tools combined 
with complete physical examination to determine specif-
ic diagnostic suspicion2,3,4.
Most diagnostic algorithms do not take into account 
individual data or prevalence each disease or prevalence 
in a given population; rather they involve information 
on clinical course of myelopathy, neuroimaging and oth-
er complementary investigation. Although we apply the 
same diagnostic flowcharts in our population, many eti-
ologies are known to be distinct in our context, notably 
the higher prevalence of infectious causes. Moreover, the 
use of flowcharts without appropriated clinical context 
increases the health system costs, while maintaining the 
high percentage of undefinited etiology cases. The aim of 
this study was to describe a large cohort of patients with 
non-traumatic myelopathy from a neurological reference 
service in Brazil.
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ABSTRACT
Non-traumatic myelopathies represent a heterogeneous group of neurological conditions. Few studies report clinical and 
epidemiological profiles regarding the experience of referral services. Objective: To describe clinical characteristics of a non-traumatic 
myelopathy cohort. Method: Epidemiological, clinical, and radiological variables from 166 charts of patients assisted between 2001 
and 2012 were compiled. Results: The most prevalent diagnosis was subacute combined degeneration (11.4%), followed by cervical 
spondylotic myelopathy (9.6%), demyelinating disease (9%), tropical spastic paraparesis (8.4%) and hereditary spastic paraparesis 
(8.4%). Up to 20% of the patients presented non-traumatic myelopathy of undetermined etiology, despite the broad clinical, 
neuroimaging and laboratorial investigations. Conclusion: Regardless an extensive evaluation, many patients with non-traumatic 
myelopathy of uncertain etiology. Compressive causes and nutritional deficiencies are important etiologies of non-traumatic 
myelopathies in our population.
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RESUMO
As mielopatias não-traumáticas representam um grupo heterogêneo de doenças neurológicas. Poucos estudos descrevem os 
perfis clínico e epidemiológico sobre a experiência de serviços de referência. Objetivo: Descrever as características clínicas de 
uma coorte de mielopatia não-traumática. Método: Os registros clínicos de 166 pacientes atendidos entre 2001 e 2012 foram 
revisados e variáveis epidemiológicas, clínicas e radiológicas foram compiladas. Resultados: O diagnóstico mais prevalente foi 
o de degeneração combinada subaguda (11,4%), seguido por mielopatia espondilótica cervical (9,6%), doenças desmielinizantes 
(9%), paraparesia espástica tropical (8,4%) e paraparesia espástica hereditária (8.4%). Aproximadamente 20% dos pacientes 
apresentaram mielopatia não-traumática de etiologia indeterminada, apesar da ampla investigação clínica, laboratorial e 
de neuroimagem. Conclusão: Independentemente da ampla avaliação, muitos pacientes com mielopatia não-traumática 
apresentam etiologia incerta. Causas compressivas e deficiências nutricionais permanecem como etiologias importantes de 
mielopatias não-traumáticas.
Palavras-chave: doenças medulares, mielite, paraparesia, mielopatia.
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METHOD
A retrospective observational review from 1050 medi-
cal records of patients was performed and 166 patients with 
suspected myelopathy. Our study was approved by our in-
stitutional Ethics Committee. All patients were followed for 
at least 2 years and underwent clinical, laboratorial, neuro-
imaging and genetic evaluation. Inclusion criteria were pa-
tients of any age or  gender, who presented at the initial clin-
ical examination with one or more clinical signs suggestive 
of possible myelopathy: sphincter dysfunction, paraparesis, 
tetraparesis, sensory level, clinical compromise of multiple 
ascendants or descendants tracts and/or a specific spinal 
cord syndrome (complete, posterior cord, anterior horn, fora-
men magnum, central cord, conus medullaris, cauda equina, 
Brown-Séquard and tractopathies) 2,3,5,6.
Information on age, gender, age at onset, disease duration, 
first clinical complaint, personal and familial medical histo-
ry, myelopathy severity (European-Myelopathy Score (EMS), 
Cooper-myelopathy-scale (CMS), Prolo-score and Nurick-score)7, 
neuroimaging studies (spinal cord MRI, eventually all neuraxi-
al), general and specific laboratory exams (routine rheumatol-
ogy profile; serum vitamin B12; angiotensin-converting enzyme; 
CMV antigenemia assay; HIV, HTLV-I/II, syphilis, hepatitis B 
and C serologies; serum very long-chain fatty acids; serum and 
urinary ceruloplasmin and copper; serum anti-aquaporin-4 an-
tibody), specific cerebrospinal fluid studies (viral and syphilis se-
rologies and oligoclonal bands)3,5,8, and electroneuromyography 
study findings (in doubtful etiology or need for additional diag-
nostic strategy) were compiled.
RESULTS
Clinical and epidemiological data
There was a slight male predominance (53%) in our sam-
ple. The mean age at diagnosis 48.5 ± 16.2 years and mean 
disease duration of 49.9 ± 34.5 months.
The most common complaints were paraparesis (41.6%; 
n = 69) and paresthesia/numbness in the lower limbs (36.1%; 
n = 60), followed by hypoesthesia in the lower limbs (18.7%; 
n  =  31), back pain (17.5%; n  =  29), monoparesis (13.8%; 
n  =  23), lower limbs pain (12.0%; n  =  20), imbalance (9.0%; 
n = 15), recurrent falls (7.2%; n = 12), sphincter disturbance 
(6.0%; n = 10), stiffness in the lower limbs (5.4%; n = 9) and 
tetraparesis (4.8%; n = 8).
Most patients presented progressive (53%; n  =  88) and 
stable (45.2%; n = 75) clinical courses, with only 2% (n = 3) 
of cases presenting recurrent deficits, all revealing demyelin-
ating disease. Only half of patients presented sphincter im-
pairment complaint (51.2%), more frequently urinary incon-
tinence (35.5%) and constipation (36.7%). Fecal incontinence 
was observed in less than 10% of cases. Double sphincter im-
pairment was most common in neuroschistosomiasis, pos-
sibly related to lesions near the conus medullaris. Evidence 
of sensory level in the physical examination was absent in 
73.5% (n = 122) of cases, and the most common level was the 
thoracic (20.5%; n  =  34). Cervical level was rarely observed 
(1.8%; n = 3).
Regarding previous medical history of chronic clinical 
and surgical conditions, draws attention the fact that only 4% 
of patients do not have medical backgrounds, as well as the 
high prevalence of previous malignancies (13.8%) (Table 1). 
A positive family history (parents, siblings) for a known etiol-
ogy of myelopathy was absent in this sample. However, up  to 
10% of patients presented with a family history of stroke, 2.4% 
(n = 4) with monoparesis of unknown etiology, and less than 
2% with family history of epilepsy, Parkinson’s disease, my-
asthenia gravis and X-linked adrenoleukodystrophy. Parental 
consanguinity was present in only 3 cases.
The most frequent non-traumatic etiologies were sub-
acute combined degeneration (11.4%), cervical spondylot-
ic myelopathy (9.6%), demyelinating disorders (9%), HTLV-
related tropical spastic paraparesis (8.4%), hereditary spastic 
paraparesis (4.8%) and schistosomal myeloradiculopathy 
(3.6%) (Table 2). Undefined etiology represented 20.5% of 
Table 1. Group of medical comorbidities and prior clinical conditions presented by patients in this study (n = 166). Only 7 
patients (4,2%) did not show any significant past medical history. Percentage among myelopathic patients are represented 
between brackets.
Relative frequency Relevant past medical history
> 25% Smoking (39.2%), hypertension (30.7%), alcoholism (26.5%).
10-25% Prior malignancy (13.8%), hypercholesterolemia (13.2%), depression (11.5%), hypothyroidism (10.2%).
5-10% Chronic gastritis and hypertriglyceridemia (9.6%), urinary tract infection repeat (8.4%), diabetes mellitus type 2 
(7.8%), megaloblastic anemia (6.0%).
< 5% 4.8%: AIDS.
4.2%: Schistosomiasis, Helicobacter pylori infection, prior sexually transmitted diseases.
3%: epilepsy, primary headache, deep vein thrombosis.
2.4%: Hepatitis C vírus infection, prior pulmonary tuberculosis.
1.8%: abortions, morbid obesity, viral poliomyelitis, prior stroke and acute myocardial infarction, hematologic 
malignancy, cirrhosis.
1.2%: herpes zoster, parkinsonism, chronic atrial fibrillation, illicit drug abuse, Chagas disease.
0.6%: chronic kidney disease on dialysis, renal tuberculosis, optic neuritis, anterior uveitis, pulmonary 
thromboembolism, histiocytosis, diabetes mellitus type 1.
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cases. In cases of hereditary spastic paraparesis, genetic test-
ing for each subtype was routinely unvailable in our service, 
regarding the diagnosis in familial patterns of neurological 
involvement and neuroimaging findings. Paraneoplastic eti-
ology was not evinced in our sample. Spondylotic cervical 
myelopathy was the cause with higher average age of patients 
at diagnosis. Demyelinating diseases, tropical spastic parapa-
resis and Chiari type I malformation presented the profile of 
younger patients, as well as neuroschistosomiasis although 
some patients discrepant.
Regarding the functional clinical severity scale applied 
(European myelopathy score/EMS) and other myelopathy 
scores (Cooper myelopathy score, Prolo-Score, Nurick-Score), 
there was no correlation of greater or lesser severity and 
functional impairment with specific etiologies (Table 3).
Laboratory results and spinal fluid analysis
Serum evaluation was performed in all patients. 
Laboratorial serum screening disclosed important results 
defining diagnosis of B12 vitamin deficiency, tropical spastic 
paraparesis, adrenomyeloneuropathy and neuromyelitis op-
tica (Table 4). There was a direct association of cases with 
high eosinophilic contents in the cerebrospinal fluid and 
schistosomal myeloradiculopathy.
Neuroimaging and neurophysiological studies
Neuroimaging studies were routinely done in all patients 
with at least one cervical and thoracic spine MRI, which in 
some cases was supplemented with cranial and lumbosacral 
imaging. In 24% (n = 40) of cases, neuroimaging evaluation 
Table 3. Results from functional clinical severity scale and other myelopathy scores.
Scale used Main results
EMS 48% score I (mild deficits), 19.3% score II (moderate deficits), < 5% score 
III (severe deficits)
CMS (upper and lower limbs compromise) 3.6% with 7 to 8 points (maximum scores), 4.2% with zero score (minimum score), 
70% with scores 1 to 6 (60% with scores 1 to 3)
Nurick score (severity of functional impairment) 48% with scores 2 to 3 (moderate functional impairment), 26% with scores higher or 
equal to 4 (severe)
Prolo score (economic and functional scale) 60% with grades II/III, 20.5% with grade I, 4.2% with normal values (grade 0)
EMS: European Myelopathy Score; CMS: Cooper Myelopathy Score.
Table 2. Main etiological groups of non-traumatic myelopathies, according to initial clinical suspicion and to definitive diagnosis 
(n = 166). Percentage among myelopathic patients are represented between brackets.
Etiological groups Relative frequency
Initial clinical suspicion Undefined (36.1%;  n = 60), Compressive (21.1%; n = 35), Subacute combined degeneration (vitamin B12 
deficiency) (11.4%; n = 19), Demyelinating (9.0%; n = 15), Hereditary spastic paraparesis (3.6%; n = 6), 
Chiari type I malformation, Schistosomal myeloradiculopathy, Tropical spastic paraparesis (3.0%; n = 5), 
Postinfectious myelitis (2.4%; n = 4), Adrenomyeloneuropathy, syringomyelia, Motor Neuron Disease (1.8%; 
n = 3). Others: spinal cord malformations (1.2%; n = 2), HIV-associated vacuolar myelopathy (0.6%; n = 1).
Definitive diagnosis Undefined (20.5%; n = 34), Subacute combined degeneration (11.4%; n = 19), Cervical canal stenosis with 
spondylotic myelopathy (9.6%; n = 16), Demyelinating (9%; n = 15) (Multiple Sclerosis 4,8%, Neuromyelitis 
optica 4.2%), Tropical spastic paraparesis (8.4%; n = 14), Hereditary spastic paraparesis (4.8%; n = 8), 
Schistosomal myeloradiculopathy (3.6%; n = 6), Spinal disk herniation (3.0%; n = 5), Chiari type I malformation, 
Vascular myelopathy and Motor Neuron Disease (2.4%; n = 4). Others: various polyneuropathies (4.8%; n = 8), 
isolated radiculopathy (3.6%; n = 6), movement disorder and syringomyelia (1.8%; n = 3), Somatoform disorder 
and spinal cord tumours (1.2%; n = 2), Spinocerebellar ataxia type 3, histiocytosis, Herpes zoster-related 
myelitis, actinic myeloradiculopathy, Sarcoidosis, Copper deficiency myeloneuropathy, CMV-related myelitis, 
cervical retrolisthesis, PSEN1-related myelopathy, Post-Polio syndrome, HIV-associated vacuolar myelopathy, 
Larsen syndrome and Lumbar canal stenosis (0.6%; n = 1).
Table 4. Main serum and cerebrospinal fluid laboratory and neuroimaging results.
Additional tests Main results
Serum laboratorial screening results 11.4% with cobalamin deficiency, 10.2% with high MCV, 9% with positive ANA, 4.2% with 
positive HTLV-I/II serologic test, 4.2% with positive anti-aquaporin-4 antibodies, < 2% 
with high VLCFA, 0.6% with copper deficiency
Cerebropinal fluid examination 3.6% with albuminocytologic dissociation, 3.6% with positive oligoclonal bands, 1.2% 
with hypereosinophilic content (> 10% of total pleocytosis)
Neuroimaging findings 23.5% with non-compressive signal changes in any segments in T2/FLAIR images; 
9.6% of cases with cervical spine stenosis (16.9% of all cases with intervertebral disc 
protrusions in the cervical segment)
Neurophysiological studies 1.8% with anterior horn cell compromise; 24.2% with demyelinating polyneuropathy; 
5.4% with isolated axonal polyneuropathy; 3.6% with isolated radiculopathy  
MCV: mean corpuscular volume; ANA: antinuclear antibody test; VLCFA: very long-chain fatty-acids.
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was unremarkable, and spinal cord signal changes were seen 
in less than a half of cases (Table 4). Some case examples are 
displayed in Figure 1.
Electroneuromyography studies were performed in only 
32% of cases, mainly in cases with suspected motor neuron 
disease, radiculopathies and myeloneuropathies, indepen-
dently from the main suspicion causes in such cases. Normal 
results were observed in 14.5% of cases. However, in less than 
2% of cases defined the diagnosis of amyotrophic lateral scle-
rosis and aided the definite diagnosis of isolated radiculopa-
thies and polyneuropathies (Table 4).
DISCUSSION
This study provides an interesting face of the main clini-
cal, epidemiological and neuroimaging findings of patients 
with non-traumatic myelopathies in our midst. Therefore, 
our sample provides a relevant view on the most common 
causes of non-traumatic myelopathies.
In Cameroon, an underdeveloped country, non-traumatic 
myelopathies are more commonly associated with compres-
sion, with 24.5% of cases accounting for neoplastic disease, 
12.9% for spinal tuberculosis and 4.1% for cervical spondylotic 
myelopathy. Other etiologies were such as for tropical spastic 
paraparesis (4.8%), 1.4% for HIV-related vacuolar myelopathy 
(1.8%), and for multiple sclerosis and subacute combined de-
generation (0.7%) are rarely reported9. No etiology was found 
in 21.1% of cases. In our population we found higher preva-
lence of vitamin B12 deficiency and demyelinating diseases.
Another large study was performed in Liverpool, England, 
in a 3-year-period with 585 patients with paraparesis or spas-
tic quadriplegia, which revealed as major causes of nontrau-
matic myelopathies cervical spondylotic myelopathy (23.6%), 
multiple sclerosis (17.8%), extrinsic spinal cord neoplasia 
(16.4%) and motor neuron disease (4.1%)10. It has also shown 
that in 18.6% of cases no specific etiologies were found, even 
after thorough etiologic investigation. In this study also the 
occurrence of neoplasms was higher and the low prevalence 
of subacute combined degeneration. Interestly, the percent-
age of patients with uknown etiology in both studies was 
very similar to our results, unvealing the difficulties inher-
ent in defining diagnosis of non-traumatic spinal cord dis-
eases. It is essential to disclose that our neurological service 
has specific neurological units which also receive subspecial-
ty cases and, thus, can explain one of the reasons for a low 
prevalence of neoplastic (such as spinal cord tumors), motor 
neuron disease (such as primary lateral sclerosis) and demy-
elinating disorders (such as neuromyelitis optica and multi-
ple sclerosis).
Other important contributions were obtained from our 
study: (i) in most cases of non-traumatic myelopathy family 
history is of little relevance; (ii) structural causes, including 
spondylotic cervical myelopathy, generally present with a lon-
ger symptom duration period; (iii) double and severe sphinc-
ter compromise are highly suggestive signs of schistosomiasis 
in our population; (iv) clinical severity of a myelopathy do not 
keep a direct relation to a specific etiology; (v) all pure mo-
tor syndromes should be evaluated with neurophysiological 
studies after a normal neuroimaging study to search for mo-
tor neuron disease, even in the absence of bulbar symptoms 
at presentation; (vi) the youngest patients were those with 
demyelinating diseases, tropical spastic paraparesis, Chiari 
type I malformation and cases of neuroschistosomiasis with-
out prominent pain complaints, as well as cervical spondy-
lotic myelopathy represents the main cause of non-traumatic 
myelopathy in the elderly. Through these findings and the 
current literature, we developed a complementary flowchart 
with a basic diagnostic algorithm for non-traumatic myelop-
athy evaluation in our population (Figure 2).
Figure 1. Some spinal cord MRI examples. (A) A 40-year-old man with a 8-month history of paraparesis, upper and lower limbs 
paresthesias with no sphincter dysfunction and a sagittal MRI section suggestive of Chiari type I malformation; (B) A 48-year-old 
man with a progressive history of recurrent longitudinally extensive transverse myelitis and a sagittal MRI section suggestive of a 
demyelinating disease with positive anti-aquaporin-4 antibody; (C) A 68-year-old man with a 4-month history of shoulder muscles 
twitching and weakness to lift objects with no sphincter dysfunction, and cervical spine MRI suggestive of cervical spondylotic 
myelopathy; (D) A 52-year-old man with a 3-week-progressive paraparesis with sagittal MRI section showing a pathological 
fracture of T10 vertebra originating from an extensive pedicular mass and giving rise to a compressive thoracic myelopathy from 
a neoplastic lesion (pathological diagnosis: plasmacytoma); (E) A 36-year-old woman with exacerbation of chronic low back 
pain associated with urinary sphincter dysfunction, paraparesis and hypoesthesia in the lower limbs, positive serological tests 
for schistosomiasis and transverse MRI section showing a T10-T11 level hyperintensity predominantly in dorsal roots, posterior 
column and lateral corticospinal tract, suggestive of schistosomal myeloradiculopathy.
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Figure 2. Myelopathy algorithm. A proposed algorithm to evaluate nontraumatic myelopathies and its main differential diagnosis. 
Fluxogram for non-traumatic myelopathy
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cause) of myelopathy?
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syndrome, tetraparesis, paraparesis, sphincter 
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spine MRI pattern? 
Spinal dural arteriovenous fistula
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Anterior spinal artery occlusion
Post viral myelitis
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